By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lumosa 

4th Floor, No. 3-2, Park Street

Nangang District  Taipei  11503  Taiwan
Phone: 886-2-26557918 Fax: 886-2-26557919


SEARCH JOBS

Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the "reSEARCH and DEVELOPMENT" model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current major products in Lumosa's pipeline are NaldebainĀ®, a long long-acting analgesic injection, and LT3001, an NCE for the treatment of acute ischemic stroke. NaldebainĀ® has received TFDA approval and launched in Taiwan in the Spring of 2017. LT3001 is under phase I clinical trial in the US.

YEAR FOUNDED:

2001

LEADERSHIP:

CEO: Wendy Huang

JOBS:

Please click here for Lumosa job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.



Key Statistics


Email:
Ownership: Public

Web Site: Lumosa
Employees:
Symbol: 6535.TWO
 



Industry
Pharmaceutical






Company News
//-->